TGA monitoring natalizumab,amid reports of melanoma

The TGA has released a monitoring communication regarding natalizumab, amid reports that three patients treated with the drug have developed melanoma.

Natalizumab, commonly known as Tysabri in Australia, is used to treat patients with relapsing-remitting multiple sclerosis to delay the progression of physical disability and reduce the frequency of relapse.

An ongoing TGA review of this issue has found insufficient evidence to indicate a definite link between natalizumab and melanoma. However, due to the high incidence of melanoma in Australia, it has issued a call for any further cases to be reported to